Souhaitez-vous accéder aux communiqués récents ?

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to ReSTART

Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT®

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026

Alpha Tau Announces New Pancreatic Cancer Data at ASCO 2026, Showcasing Combined Results from Three Alpha DaRT® Pancreatic Cancer Studies

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxan

Alpha Tau to Present at Sidoti March Virtual Small Cap Conference March 2026

- Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and...

- Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in...

TEL AVIV, Israel, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Alpha Tau Medical is happy to announce its first clinical trial in Italy. The study at IRST, Meldola, will evaluate the feasibility, safety and...